We’re a highly collaborative group, focusing on epigenetics and genomics. We investigate fundamental modes of gene regulation and how they can be disrupted in human disease.
We are motivated to understand chromatin structure in the context of epigenetic activation and repression, as we define projects at the interface of epigenomics and pediatric cancer biology. Our view is that understanding basic epigenetic mechanisms and vulnerabilities will provide the groundwork for precision therapies.
Understanding Epigenetic Regulation in Childhood Cancer
While pediatric cancers often have low mutational burden, alterations can drive changes in the epigenetic landscape. Our group seeks to understand chromatin deregulation in cancers with low mutational frequencies. We have a special interest in understanding the central determinants for 3D genome organization in cancer, defining how chromatin interactions change in human disease, and for investigating how the epigenome interacts with chemotherapeutics.
Epigenomics for Chromatin Architecture
In order to define altered epigenetic states, our group develops new methods for understanding chromatin structure, and how proteins bind to the genome. Our methods are driven by questions connecting chromatin remodeling and genome architecture.
Benjamin Stanton, PhD
Benjamin Stanton leads the Systems Epigenetics Group at Nationwide Children’s and The Ohio State University College of Medicine. His main research interests relate to understanding chromatin activation in childhood cancer, understanding how epigenetic repression influences genome organization in human disease and exploring interdisciplinary approaches for new methods in systems epigenetics. Dr. Stanton cares deeply about mentoring the next generation of scientists. He also enjoys spending time with his wife Abigail Wolf.
Caitlin Jones, PhD
I graduated with a PhD in biomedical engineering from the Ohio State University. My research in the Stanton lab focuses on understanding the epigenetic landscape in AML.
Benjamin Sunkel, PhD
My academic training is in biochemistry, and my research interests concern gene regulatory mechanisms gone awry in cancer. In the Stanton lab, I focus on the cellular machinery that modifies, restructures, and organizes the genome to facilitate appropriate gene expression levels in each of our cells. Disruption of these essential factors is a potent recipe for diseases including cancer, and we hope to leverage our findings to inform new treatment strategies in pediatric cancers.
I have a PhD from OSU with a focus in statistical genetics. I also did a postdoc studying the genetic association between rare variants and epilepsy. My lab duty is to carry out analysis for various next generation sequencing data.